6533b850fe1ef96bd12a83a1
RESEARCH PRODUCT
220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer
M. NechaevaAssen DudovMartin SchulerA. RusynG. ManikhasFlorian LordickA. PecheniyUgur SahinIgor BondarenkoO. Tu¨ ReciIgor BazinE. GotovkinBohuslav MelicharZanete ZvirbuleIhor VynnychenkoN. FadeevaY. VinnykChristoph HuberS.-e. Al-batransubject
Oncologymedicine.medical_specialtybiologybusiness.industryCancerHematologyGastroesophageal Junctionmedicine.diseaseOxaliplatinCapecitabine03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinebiology.proteinmedicine030212 general & internal medicineAntibodyClaudinbusinessIMAB362Epirubicinmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2016-12-01 | Annals of Oncology |